Zynex Inc

Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. The company also develops a new blood volume monitor for use in hospitals and surgery centers. The company was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zynex Inc (ZYXI) achieves record highs in Q4 2022

Zynex Inc (ZYXI) delivered strong financial performance in Q4 2022 and full-year 2022, projecting continued growth in 2023. The company's focus on innovation, regulatory milestones, and operational efficiency positions it well for future success.

Zynex Inc reports robust Q1 earnings, eyes revenue growth

Zynex Inc's Q1 2023 performance reflects strong revenue growth and increased orders, supported by strategic initiatives like stock buybacks.
While facing challenges in scaling the sales force and navigating market dynamics, the company is well-positioned to leverage opportunities for expansion and innovation.
Investors can look forward to continued revenue growth, product development, and potential market expansion as Zynex pursues its growth targets.

Zynex Inc reports record revenue and FDA clearances, reaffirms guidance

Zynex Inc delivered robust financial results in Q2 2023, showcasing consistent profitability and revenue growth across its divisions.
The company's focus on product innovation, FDA clearances, and strategic financial moves underscores its commitment to sustained growth and market leadership.
While facing potential challenges, Zynex Inc remains optimistic about its future outlook, aiming to capitalize on market opportunities and drive continued success.

Zynex reports record revenue and growth outlook, driven by innovation

Zynex Inc (ZYXI) delivered strong financial results in Q3 2023, driven by revenue growth, operational efficiency, and strategic product innovations.
The company's focus on noninvasive pain management solutions and commitment to regulatory milestones underscore its growth potential and market positioning.
While facing challenges such as market competition and operational scalability, Zynex's strengths in financial performance and innovation present opportunities for sustained success.

Zynex Inc (ZYXI) reports record revenue and explores strategic alternatives

Zynex Inc (ZYXI) delivered a strong performance in 2023, marked by record revenue, profitability, and operational achievements, positioning the company for continued growth and success.
While facing challenges related to strategic decision-making and operational execution, Zynex remains well-positioned to capitalize on opportunities for revenue expansion, product innovation, and market leadership.
With a focus on financial stability, product diversification, and strategic growth initiatives, Zynex is poised to navigate challenges, leverage opportunities, and drive value for shareholders in the upcoming year.

Zynex Inc reports revenue growth and FDA clearance success

Zynex Inc (ZYXI) demonstrated solid financial performance in Q1 2024, with revenue growth and positive cash flow.
The company's focus on product innovation, sales expansion, and revenue diversification positions it well for future growth.
While facing challenges such as revenue delays and strategic uncertainties, Zynex remains optimistic about its growth prospects and market opportunities.

Zynex Inc reports strong Q2 performance, eyes $200M revenue target

Zynex Inc delivered a strong Q2 2024 performance with revenue growth, improved sales efficiency, and a positive outlook for the year, targeting $200 million in total revenue.
While facing challenges in revenue diversification and sales force refinement, Zynex maintains a solid gross profit margin and a focus on operational excellence.
The company's Monitoring Solutions division shows promise, with ongoing product milestones and plans for FDA submission, indicating future growth potential and market expansion.
Strategic management of challenges and capitalizing on opportunities position Zynex well for sustained growth and profitability in the evolving healthcare market.

Zynex Inc reports strong Q3 performance and eyes growth opportunities

Zynex Inc's Q3 2024 performance reflects revenue growth, profitability, and strategic reinvestment in the business.
While facing challenges in decision-making and operational efficiency, the company is well-positioned for growth.
Opportunities in expanding sales, launching new products, and exploring partnerships pave the way for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. It also develops a new blood volume monitor for use in hospitals and surgery centers. The company was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.

Zynex, Inc. (NASDAQ:ZYXI ) Q3 2024 Earnings Conference Call October 24, 2024 4:15 PM ET Company Participants Quinn Callanan - IR Thomas Sandgaard - Chairman, President and CEO Dan Moorhead - CFO Donald Gregg - President, Monitoring Solutions Conference Call Participants Avi Dahan - RBC Capital Markets Jeffrey Cohen - Ladenburg Thalmann Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen.

Zynex, Inc. (ZYXI) Q3 2024 Earnings Call Transcript

Zynex Inc. (ZYXI) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.10 per share a year ago.

Zynex Inc. (ZYXI) Tops Q3 Earnings Estimates

Zynex Inc (NASDAQ:ZYXI) announced its third-quarter 2024 financial and operational results highlighted by a 13% year-over-year increase in orders. The pain management device company reported net revenue of $50 million for the quarter ended September 30, 2024, up slightly from $49.9 million in the prior-year period.

Zynex sees pain management orders increase in Q3 following FDA approval

ENGLEWOOD, Colo. , Oct. 24, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the third quarter ended September 30, 2024.

Zynex Reports Third Quarter 2024 Financial Results

Thomas Sandgaard is just getting started. The enigmatic “rockstar CEO” of pain management company Zynex Inc (NASDAQ:ZYXI) has worn many hats throughout his career: Sales leader, lead guitarist, football club owner (pro tip: dealing with shareholders is much easier than dealing with sports fans).

Sales, strategy, and saving lives: A conversation with Zynex CEO Thomas Sandgaard

ENGLEWOOD, Colo. , Oct. 16, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, October 24, 2024 at 4:15 PM Eastern Time to discuss its financial results for the third quarter ended September 30, 2024.

Zynex Sets Third Quarter 2024 Earnings Call

Analysts expect Zynex Inc (NASDAQ:ZYXI) to return to stronger growth in 2025, driven by product diversification, sales force expansion, and upcoming product launches. The company's strategic initiatives are seen as laying the groundwork for long-term success despite short-term hurdles.

Zynex's strategic shifts set stage for long-term success, analysts say

Zynex Inc (NASDAQ:ZYXI) CEO Thomas Sandgaard recently sat down with Proactive to discuss the medical device company's innovative solutions and impressive growth trajectory.   Sandgaard highlighted how Zynex has expanded from a one-person operation 28 years ago to a company with 1,200 employees and revenues reaching $200 million.

Zynex CEO reflects on 28 years of medical device innovation - ICYMI

ZYXI recently received the Food and Drug Administration clearance for its new TensWave device. TensWave is designed to provide a comprehensive pain management solution.

Zynex Stock Rises on FDA Clearance of Its New Pain Management Device

ENGLEWOOD, Colo. , Sept. 4, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced it will present at the upcoming HC Wainwright Global Investment Conference, which is being held September 9-11, 2024.

Zynex to Present at the HC Wainwright Global Investment Conference

Zynex Inc (NASDAQ:ZYXI) announced that its portable pain management device TensWave has achieved Food and Drug Administration (FDA) clearance. The prescription-only TensWave device aims to provide pain relief through TENS (Transcutaneous Electrical Nerve Stimulation) therapy, which the company highlighted has been clinically proven to reduce chronic and acute pain without needing medication.

Zynex pain management device TensWave achieves FDA clearance

ENGLEWOOD, Colo. , Sept. 3, 2024 /PRNewswire/ -- Zynex Inc. (NASDAQ: ZYXI), a leading medical technology company specializing in non-invasive medical devices for pain management and rehabilitation, today announced FDA clearance of its new TensWave device.

Zynex Obtains FDA clearance for new Pain Management Device

Growth versus value: It's a classic dilemma for investors. Choosing growth often demands a leap of faith—buying into a management team's vision of a significant commercial opportunity that may require patience and substantial financial investment to realize.

Zynex's bold expansion in patient monitoring technologies moves from vision to reality

Zynex missed on second-quarter revenue and earnings, and guided down. However, some of the near-term weakness was by design, as the company is cutting costs.

Why Zynex Plunged Today

Zynex (NASDAQ: ZYXI ) stock is falling on Friday following the release of the medical device maker's earnings report for the second quarter of 2024. This starts with diluted earnings per share of 4 cents.

Why Is Zynex (ZYXI) Stock Down 24% Today?

DexCom

Olin

U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Friday.

DexCom, Zynex, Olin And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Zynex, Inc. (NASDAQ:ZYXI ) Q2 2024 Earnings Conference Call July 23, 2024 4:15 AM ET Company Participants Thomas Sandgaard - Chairman, President & Chief Executive Officer Dan Moorhead - Chief Financial Officer Donald Gregg - President, Zynex Monitoring Solutions Quinn Callanan - MZ North America Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Zynex Second Quarter 2024 Earnings Conference Call.

Zynex, Inc. (ZYXI) Q2 2024 Earnings Call Transcript

Zynex Inc. (ZYXI) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.09 per share a year ago.

Zynex Inc. (ZYXI) Q2 Earnings and Revenues Lag Estimates

Q2 2024 Revenue Increased 11% to $49.9 Million ENGLEWOOD, Colo. , July 25, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the second quarter ended June 30, 2024.

Zynex Reports Second Quarter 2024 Financial Results

ENGLEWOOD, Colo. , July 17, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, July 25, 2024 at 4:15 PM Eastern Time to discuss its financial results for the second quarter ended June 30, 2024.

Zynex Sets Second Quarter 2024 Earnings Call

ENGLEWOOD, Colo. , July 11, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it has been recognized for multiple awards by Top Workplaces and the U.S. News & World Report 2024-2025 ratings.

Zynex Recognized as a Best Company to Work For by U.S. News & World Report and Top Workplaces

Advantage Solutions

EVgo

Forward Air

Sunnova Energy International Inc

Children's Place

Trupanion

In 2021, a trader with a large Reddit following induced a massive rally in shares of GameStop Corp. NYSE: GME. The downtrodden gaming retailer was the most shorted stock in the entire market in January 2021, but the retail buying frenzy triggered a massive run-up in price as hedge funds were forced to cover their short positions to prevent huge losses.

7 Short Squeeze Stocks to Look Into for Your Portfolio

Zynex (ZYXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Zynex (ZYXI) Rating Upgrade to Buy

Mondee Holdings Inc

Nuvalent

Generally, when the masses – including the market's heavy hitters – decide to bet against a security, it's best to avoid it. However, the unique nuances involved with shorting a company opens the door for the contrarian trade.

3 Short-Squeeze Stocks Poised for a Jaw-Dropping Rally

Celsius Holdings

Hilton Worldwide Holdings

Tracking information on which stocks to buy can be a daunting and time-consuming process. One way to streamline it is to consider analyst EPS, growth and other forecasts, as well as price targets.

News for Zynex Inc Stock (ZYXI)